


# Brimonidine tartrate



## CAS

70359-46-5

## Status

Commercial

[Inquiry](#)

Brimonidine tartrate is an imidazolin derivative that is a selective agonist of  $\alpha_2$ -adrenoceptors. As it binds less to  $\alpha_1$ -adrenoceptor, the side effects it mediates decrease. It acts sympathomimetic. Due to the lower chamber water formation and the increased uveoscleral outflow, the intraocular pressure decreases in the open-angle glaucoma (reserve drug). It can also be used to treat facial erythema, as it leads to the constriction of blood vessels in the facial area.

## Description

**Formula**  $C_{11}H_{10}BrN_5O_2 \cdot C_4H_6O_4$

**Molecular weight** 442.22 g/mol

**Molecular size** small

**Controlled Substance** no

**Precursor** no

**Indications** Ophthalmological drugs

## Your Contact



**Marius Hang**  
*International Division*  
*Director API Export*

Midas Pharma GmbH  
Rheinstr. 49  
55218 Ingelheim  
Germany  
[Send E-Mail](#)

### Disclaimer

*The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.*

*No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.*